Great Point Partners’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Great Point Partners’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,273,509	Closed	-$9.49M	–	50
2017 Q3	$9.49M	Sell	3,273,509 -3,950,000	-55%	-$13.5M	1.85%	20
2017 Q2	$32.1M	Hold	7,223,509	–	–	5.76%	6
2017 Q1	$33.7M	Buy	7,223,509 +2,250,000	+45%	+$13M	6.69%	3
2016 Q4	$30.3M	Sell	4,973,509 -1,448,723	-23%	-$7.57M	6.22%	4
2016 Q3	$35.4M	Sell	6,422,232 -1,167,768	-15%	-$5.47M	9.03%	3
2016 Q2	$28.8M	Buy	7,590,000 +5,415,000	+249%	+$18.4M	8.26%	3
2016 Q1	$6M	Buy	2,175,000 +628,112	+41%	+$2.27M	2.15%	18
2015 Q4	$8.77M	Buy	1,546,888 +411,308	+36%	+$2.51M	3.68%	9
2015 Q3	$6.02M	Sell	1,135,580 -874,404	-44%	-$6.77M	2.38%	18
2015 Q2	$16.7M	Buy	+2,009,984	New	+$9.74M	6.5%	5

Other funds holding SGYP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Great Point Partners's SGYP Position: Q4 2017 in Review

Great Point Partners sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 3,273,509 shares — an estimated $9.49M sold.

Great Point Partners first reported a position in SGYP in Q2 2015 and held it in 10 quarters. The position peaked at $35.4M in Q3 2016. 149 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

Great Point Partners reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
Great Point Partners sold 3,273,509 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $9.49M.
Great Point Partners first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2015 and held it in 10 quarters.
Great Point Partners's Synergy Pharmaceuticals, Inc Common Stock position peaked at $35.4M in Q3 2016.
149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on Great Point Partners's 13F filing for Q4 2017, filed 14 Feb 2018.